BioVie Presents New Biomarker Data Highlighting Biomarker-Defined Endotypes and Neuropeptide Y Response to Bezisterim at the 4th Long COVID International Conference 2026
Globe Newswire•16/11/2026•08:00 ET
0
Key Highlights
- ➤Bezisterim cut neuropeptide Y abundance approximately 33% at Week 12, q≈0.01
- ➤High-inflammatory endotype showed cognitive improvement, Cohen’s d≈0.83; p=0.001
- ➤Low-WBC/low-myeloid endotype showed fatigue and PEM effects, Cohen’s d≈0.80-0.90
- ➤ADDRESS-LC overall population missed statistical significance across all endpoints
- ➤Bezisterim adverse events were 41.6% versus 55.9% for placebo
Expert Statements
Penelope Markham, PhD; leads BioVie’s Long COVID clinical development program
“Long COVID is unlikely to represent a single biological disease state, and our findings suggest that differences matter and may play an important role in treatment response”
Penelope Markham, PhD; leads BioVie’s Long COVID clinical development program
“The identification of biomarker-defined endotypes associated with clinical response, together with bezisterim-associated reductions in NPY across these groups, provides important insights into which patients may benefit most from treatment, and how bezisterim may be affecting underlying disease biology.”
Penelope Markham, PhD; leads BioVie’s Long COVID clinical development program
“The addition of NPY to the RECOVER biomarker prioritization list further underscores the importance of investigating this neuroimmune signal.”
Penelope Markham, PhD; leads BioVie’s Long COVID clinical development program
“Together these findings provide a strong rationale for a more targeted precision-medicine approach to future Long COVID trials.”
New findings from the Phase 2 ADDRESS-LC trial identify two distinct biomarker-defined Long COVID endotypes(1 )associated with different patient responses to bezisterim treatment.
Bezisterim treatment was associated with a statistically significant reduction in neuropeptide Y
Get started
Create a free account to read the full story.
